Compumedics (ASX:CMP) reported record sales orders taken of AU$32.8 million for the first half of fiscal 2025, up 55% year on year, according to a Wednesday filing with the Australian bourse.
The total does not include the company's MEG brain imaging technology.
The US division drove growth as sales surged 208%, the filing said. Asian booked sales orders rose 115%, while European sales grew 10%.
The medical device maker expects reported revenue of AU$23.2 million for the first half, down 13% on the year-earlier period. Excluding MEG, first-half revenue is forecast to be 6% higher year on year.
For fiscal 2025, the company anticipates sales of more than AU$55 million, excluding MEG. It also expects earnings before interest, taxes, depreciation, and amortization of above AU$5 million.
Compumedics' shares rose almost 11% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.